stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) EPS (diluted)
BeOne Medicines Ltd. - Sponsored ADR's EPS (diluted) for fiscal 2025 was $2.53, compared with −$6.12 in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.68. Over the past ten years it has ranged from −$19.43 (fiscal 2022) to $2.53 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. BeOne Medicines Ltd. - Sponsored ADR ranks 14th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.53 | — |
| FY2024 | −$6.12 | — |
| FY2023 | −$8.45 | — |
| FY2022 | −$19.43 | — |
| FY2021 | −$15.23 | — |
| FY2020 | −$19.13 | — |
| FY2019 | −$15.80 | — |
| FY2018 | −$12.15 | — |
| FY2017 | −$2.23 | — |
| FY2016 | −$3.84 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $2.05 | 4.59% |
| Mar 2026 | $1.96 | 237.93% |
| Dec 2025 | $0.58 | (46.79%) |
| Sep 2025 | $1.09 | 29.76% |
| 41 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ARGX argenex SE compare | $28.66 |
| ONC BeOne Medicines Ltd. - Sponsored ADR | $5.68 |
| INCY Incyte Corporation compare | $1.88 |
| RPRX Royalty Pharma PLC compare | $1.40 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| INSM Insmed, Inc. compare | −$2.82 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
| RVMD Revolution Medicines, Inc. compare | −$9.11 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ONC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement